USPTO serial 87770621
AOBIOME
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BURDECKI, ANNA C
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AOBIOME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Cambridge, MA
Cambridge, MA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ann Lamport Hammitte
Ann Lamport Hammitte LANDO & ANASTASI, LLP60 State Street, 23rd FloorBoston, MA 02109UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicated gels for therapeutic use in the nature of therapeutic pharmaceuticals containing ammonia oxidizing bacteria for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; medicated creams for therapeutic use in the nature of therapeutic pharmaceuticals containing ammonia oxidizing bacteria for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; medicated sprays for therapeutic use in the nature of therapeutic pharmaceuticals containing ammonia oxidizing bacteria for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; nasal sprays for therapeutic use; topical applications in the nature of gels, creams, sprays, and liquids for therapeutic use, namely, topical preparations containing ammonia oxidizing bacteria for the treatment of skin disorders, acne, inflammation, eye disorders, migraines, headaches, allergic reactions, insomnia, hypertension, thermoregulation, and to promote wound healing; medicated liquids for therapeutic use in the nature of therapeutic pharmaceuticals for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; biological therapeutics being pharmaceutical preparations for treatment of skin disorders, circulatory and cardiovascular disorders, neurologic diseases, inflammation, gastrointestinal disorders, respiratory disorders, eye disorders, urogenital disorders, auditory disorders, migraines, headaches, allergic rhinitis, insomnia, hyperhidrosis, acne, and hypertension; therapeutic agents for thermoregulation and promoting wound healing | ACTIVE | — |
| 010 | Stents; intra-uterine contraceptive devices; catheters; pessaries; coatings sold as an integral component of medical stents and other implantable medical devices | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 11, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 11, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 19, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 18, 2021 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 18, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 16, 2021 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 16, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 11, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 9, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 9, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 9, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 4, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 2, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 2, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 2, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 6, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 4, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 4, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 4, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 24, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 22, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 22, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 22, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 22, 2019 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 22, 2019 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 5, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 8, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 8, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 19, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 20, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 20, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 20, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 20, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 20, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 13, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 13, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 15, 2018 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 15, 2018 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 15, 2018 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| May 7, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 6, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 29, 2018 | NWAP | NEW APPLICATION ENTERED | — |